AWA
BIIB icon

Arete Wealth Advisors’s Biogen BIIB Stock Holding History

Arete Wealth Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,060
Closed -$363K – 362
2025
Q4 		$363K Buy
+2,060
New +$337K 0.02% 533
2024
Q3 		– Sell
-878
Closed -$204K – 721
2024
Q2 		$204K Buy
+878
New +$191K 0.02% 659

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Arete Wealth Advisors's BIIB Position: Q1 2026 in Review

Arete Wealth Advisors sold out of Biogen (BIIB) in Q1 2026, closing a stake of 2,060 shares — an estimated $363K sold.

Arete Wealth Advisors first reported a position in BIIB in Q2 2024 and held it in 2 quarters. The position peaked at $363K in Q4 2025. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Arete Wealth Advisors reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
  • Arete Wealth Advisors sold 2,060 Biogen shares in Q1 2026, an estimated $363K.
  • Arete Wealth Advisors first reported a position in Biogen in Q2 2024 and held it in 2 quarters.
  • Arete Wealth Advisors's Biogen position peaked at $363K in Q4 2025.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Arete Wealth Advisors's 13F filing for Q1 2026, filed 18 May 2026.